Core Viewpoint - Sionna Therapeutics is focused on transforming the treatment of cystic fibrosis (CF) by developing innovative medicines that normalize the function of the CFTR protein [2]. Company Overview - Sionna Therapeutics is a clinical-stage biopharmaceutical company dedicated to revolutionizing CF treatment through novel medicines aimed at restoring CFTR function [2]. - The company aims to deliver differentiated therapies that stabilize the nucleotide binding domain 1 (NBD1) of the CFTR protein, which is believed to be crucial for improving clinical outcomes and quality of life for CF patients [2]. - Sionna is advancing a pipeline of small molecules designed to correct defects caused by the F508del genetic mutation in NBD1 and is also developing complementary CFTR modulators to enhance CFTR function [2]. Investor Engagement - Sionna will participate in investor events, including the Cantor Global Healthcare Conference on September 3, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025 [4]. - Live webcasts of these presentations will be available on the company's Investor Relations website, with replays accessible after the events [1][3].

Company Overview - Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein [3] - The company aims to deliver differentiated medicines that restore CFTR function to near-normal levels by directly stabilizing CFTR's nucleotide-binding domain 1 (NBD1), which is believed to be crucial for improving clinical outcomes and quality of life for CF patients [3] Pipeline and Research Focus - Sionna is advancing a pipeline of small molecules engineered to correct defects caused by the F508del genetic mutation located in NBD1 [3] - The company is also developing a portfolio of complementary CFTR modulators designed to work synergistically with its NBD1 stabilizers to enhance CFTR function [3] Upcoming Events - Management will present at The Citizens Life Sciences Conference on May 7, 2025, at 12:30 p.m. ET [1] - A live webcast of the presentation will be available on the company's Investor Relations website, with a replay accessible for 90 days post-event [2]

WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 12:30 p.m. ET. A live webcast of the prese ...